Abstract:Sathyaprasad Burjonrappa Department of Pediatric Surgery, Rutgers, State University of New Jersey, New Brunswick, NJ, USA Comment on: Weil BR, Murphy AJ, Liu Q, et al . Late Health Outcomes Among Survivors of Wilms Tumor Diagnosed Over Three Decades: A Report From the Childhood Cancer Survivor Study. J Clin Oncol 2023;41:2638-50. Keywords: Wilms tumor (WT); chronic health conditions; late health outcomes; second malignant neoplasm Submitted Dec 03, 2023. Accepted for publication Jan 16, 2024. Published online Feb 27, 2024. doi: 10.21037/tp-23-579 It is a pleasure to write the editorial commentary on a landmark paper by Weil and colleagues recently published in the Journal of Clinical Oncology (1). The improvement in Wilms tumor (WT) survival, with 85–90% 5-year survivals, can be attributed to risk adjusted standardization of therapy based on protocols developed by the Children's Oncology Group (COG) in the United States (USA) and SIOP (Societie International Oncology Pediatrique) in Europe over the last half century. The focus has now rightly shifted to understanding long-term health consequences in WT survivors of current treatment protocols. The paper was very well designed to study the long-term health related disease burden and suggest potential changes to treatment paradigms by understanding the consequences of risk adjusted multimodal therapy. It evaluated the incidence of long-term morbidity after treatment for unilateral nonsyndromic WT in a cohort of 2,008 survivors by studying the 35-year cumulative incidence of death and development of any grade 3–5 chronic health condition (CHC) to a matched cohort (2:1) of siblings of cancer survivors. WT patients in the cohort were treated between 1970 and 1999. The use of the Childhood Cancer Survivor Study (CCSS) and linking it to the National Death Index helped establish late mortality (beyond 5 years of therapy) and cause of death in the study. The authors proceed to further classify late deaths as due to WT relapse, other health related causes (including late effects of therapy), or external causes. Subsequent Malignant Neoplasm (SMN) incidence was ascertained by self-reporting and medical record review. CHCs were graded according to Common Technology Criteria for Adverse Events (CTCAE) as mild (Grade 1); moderate (Grade 2); disabling (Grade 3); life threatening (Grade 4); and fatal (Grade 5). In selecting grade 3–5 CHCs for further study the authors have rightly focused on the most commonly known causes of morbidity after WT surgery including intestinal obstruction needing operative intervention, kidney failure requiring dialysis or transplant, heart failure, and Premature Ovarian Insufficiency (POI) before age 40 years in females. Standardized Short Form-36 answers dichotomized to impaired/non impaired was used to subjectively measure health related quality of life (HRQOL). Covariates included demographic data and treatment exposure. Chemotherapy (CT) exposure was evaluated based on established WT regimens while radiotherapy (RT) exposure was subdivided to (I) ipsilateral flank RT; (II) whole abdominal RT (WART); and (III) whole lung RT (WLRT). Further exposure was evaluated by RT site and RT dose. Survivors were stratified for two field categories [WLRT and abdominal radiotherapy (ART)] and dose was categorized as ≥20 or ≤20 Gy. The authors have included all variables that affect risk for CHCs after WT treatment and develop treatment attributable risk based on exposure. Median age of survivor cohort at diagnosis and follow-up were 3.2 years (range, 0–20.2 years) and 27.8 years (range, 6.4–57.5 years). The true merit of this study lies in the length of follow-up that has been obtained. All survivors in cohort had undergone nephrectomy and nearly all (98.1%) received CT with vincristine (93.8%) and actinomycin D (93.5%) while doxorubicin was used in 44.8%. Use of other agents (etoposide, cyclophosphamide, and platinum agents) was more common after the 1990's as compared to those treated in the 70's and 80's. As would be expected, with greater disease burden, treatment group with >4 medications had the greatest proportion of survivors experiencing early relapse (23.2%). Doxorubicin use was also more common over time but cumulative dose exposure (≥250 mg/m 2 ) decreased over time. Fifty-five percent of survivors received RT with most common fields being flank (27.8%); WART (13.8%) and WLRT (13.4%). There were 142 late deaths (7.8%). Most importantly health related mortality (4.7%) was nearly three times relapse-related mortality (1.6%). This I believe is going to be important in making treatment decisions in the future. Most frequent causes of death were SMN (n=42), WT relapse (n=30), and cardiac. (n=9). Breast cancer was the most commonly reported SMN [standardized incidence ratio (SIR) of 4.1] and was highest in the group that received VAD (vincristi -Abstract Truncated-

Prevention of treatment abandonment remains an important challenge to increase survival of Wilms tumor in sub‐Saharan Africa: A report from Wilms Africa—CANCaRe Africa

Effectiveness of a Wilms tumour treatment guideline adapted to local circumstances in sub‐Saharan Africa: A report from Wilms Africa Phase II—CANCaRe Africa

Surgical aspects and outcomes after nephrectomy for Wilms tumour in sub‐Saharan Africa: A report from Wilms Africa Phase II—CANCaRe Africa

Treatment abandonment in children with Wilms tumor at a national referral hospital in Uganda

Reflections on 20 years of the Wilms Africa project: Lessons learned and the way forward

The prognostic relevance of preoperative transcatheter arterial chemoembolization (TACE) and PCNA/VEGF expression in patients with Wilms' tumour.

A 5-year multidisciplinary care outcomes in children with wilms' tumour managed at a tertiary centre: A retrospective observational study

Towards zero percent treatment abandonment of patients with common and curable childhood cancer types in Blantyre, Malawi

Survival characteristics of Wilms Tumor, a reference developed from a longitudinal cohort study

Outcomes of relapsed favorable‐histology Wilms tumor in non‐clinical trial setting

Treatment guideline concordance, initiation, and abandonment in patients with non-metastatic breast cancer from the African Breast Cancer-Disparities in Outcomes (ABC-DO) cohort in sub-Saharan Africa: a prospective cohort study

Late health outcome among survivors of Wilms tumor

Survival of children with endemic Burkitt lymphoma in a prospective clinical care project in Uganda

Current Treatment for Wilms Tumor: COG and SIOP Standards

Prognostic Factors and Outcome of Wilms' Tumour in A Tertiary Children'S Hospital, China

Cancer survival in sub-Saharan Africa (SURVCAN-3): a population-based study

Retrospective analysis of pediatric patients with Burkitt lymphoma treated in Tanzania following the implementation of the 2016 National Treatment Guidelines: Poor outcomes to current standard‐of‐care therapy

Safety, efficacy, and affordability of ABVD for Hodgkin lymphoma in Malawi: a prospective cohort study

Impact of the First Generation of Children's Oncology Group Clinical Trials on Clinical Practice for Wilms Tumor

A long-term follow-up report of pediatric relapsed Wilms tumor after retreatment

Omission of adjuvant chemotherapy in patients with completely necrotic Wilms tumor stage I and radiotherapy in stage III: The 30‐year SIOP‐RTSG experience